A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

abstract：UNLABELLED:Patients with prior virologic failure (VF) are at an increased risk of subsequent failure, emergence of resistance, and death. This analysis identifies outcomes and correlates of VF in a high-risk population. METHODS:A5251 was designed to evaluate an enhanced adherence counseling intervention delivered by n...

journal_title：HIV clinical trials

authors： Robbins GK,Cohn SE,Harrison LJ,Smeaton L,Moran L,Rusin D,Dehlinger M,Flynn T,Lammert S,Wu AW,Safren SA,Reynolds NR

更新日期：2016-07-01 00:00:00

abstract：PURPOSE:Questionnaires assessing patient-reported outcomes in HIV are either too long or not HIV-specific. Our aim was to develop and validate a simplified HIV patient questionnaire. METHOD:607 HIV patients treated with a combination of antiretroviral (ARV) drugs were enrolled in an observational, longitudinal study. ...

journal_title：HIV clinical trials

authors： Spire B,Arnould B,Barbier F,Durant J,Gilquin J,Landman R,Carret S,Saussier C,El Kebir S,Cohen-Codar I

更新日期：2009-07-01 00:00:00

abstract：BACKGROUND:Effective and easy to implement interventions to improve adherence to antiretroviral therapy are needed. OBJECTIVE:To compare site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy to the study site's standard of care. METHODS:A rando...

journal_title：HIV clinical trials

authors： Robbins GK,Testa MA,Su M,Safren SA,Morse G,Lammert S,Shafer RW,Reynolds NR,Chesney MA

更新日期：2013-09-01 00:00:00

abstract：BACKGROUND:Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients. METHODS:Diagnostic study to determine immune response against the H1N1v com...

journal_title：HIV clinical trials

authors： Bickel M,Lassmann C,Wieters I,Doerr HW,Herrmann E,Wicker S,Brodt HR,Stephan C,Allwinn R,Jung O

更新日期：2013-07-01 00:00:00

abstract：OBJECTIVES:ARTEMIS demonstrated significantly greater efficacy of once-daily darunavir/ritonavir (DRV/r) 800/100 mg versus lopinavir/ritonavir 800/200 mg (total daily dose) in treatment-naïve, HIV-1-infected patients at week 96. The influence of baseline characteristics on efficacy and safety was analyzed in DRV/r pati...

journal_title：HIV clinical trials

authors： Fourie J,Flamm J,Rodriguez-French A,Kilby D,Domingo P,Lazzarin A,Ballesteros J,Sosa N,Van De Casteele T,DeMasi R,Spinosa-Guzman S,Lavreys L

更新日期：2011-11-01 00:00:00

abstract：BACKGROUND:Despite the high prevalence of HIV in correctional settings, the duration of therapy and response to various highly active antiretroviral therapy (HAART) regimens in this setting is unknown. METHOD:Using a retrospective cohort study (1997-2002) of HIV-infected prisoners in Connecticut that linked demographi...

journal_title：HIV clinical trials

authors： Springer SA,Friedland GH,Doros G,Pesanti E,Altice FL

更新日期：2007-07-01 00:00:00

abstract：BACKGROUND:Impaired allostimulatory function of dendritic cells in patients with AIDS has been reported previously. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can restore the T-cell stimulatory function in transforming growth factor-beta 1 (TGF-beta 1)-inhibited murine accessory cells. We now report the ...

journal_title：HIV clinical trials

authors： Bernstein ZP,Brooks SP,Chanan-Khan A,Gollnick SO,Gilbert MJ,Miller KC,Tomasi TB

更新日期：2002-05-01 00:00:00

abstract：BACKGROUND:We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coinfected persons. METHODS:Prospective, single-arm study in which subjects received ...

journal_title：HIV clinical trials

authors： Amorosa VK,Luetkemeyer A,Kang M,Johnson VA,Umbleja T,Haas DW,Yesmin S,Bardin MC,Chung RT,Alston-Smith B,Tebas P,Peters MG

更新日期：2013-11-01 00:00:00

abstract：BACKGROUND:The best method for assessment of functional status in human immunodeficiency virus type 1 (HIV-1) infected persons is unknown. OBJECTIVE:We hypothesized that 3 instruments to assess frailty or disability in elderly populations would perform similarly in HIV-1-infected persons. METHODS:HIV-infected subject...

journal_title：HIV clinical trials

authors： Erlandson KM,Allshouse AA,Jankowski CM,Duong S,Mawhinney S,Kohrt WM,Campbell TB

更新日期：2012-11-01 00:00:00

abstract：METHOD:Analysis of virological, immunological, and clinical data over 24 weeks of treatment of drug-experienced patients administered didanosine (ddI) and tenofovir (TDF) plus either PI or NNRTI (17 patients) compared to 14 patients on ddI plus lamivudine and to 19 patients on ddI plus stavudine. RESULTS:Patients trea...

journal_title：HIV clinical trials

authors： Di Biagio A,Beltrame A,Cenderello G,Ferrea G,De Maria A

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:In recent ritonavir-boosted protease inhibitor (PI) studies, high efficacy rates have been observed, with few PI mutations detected. METHOD:To better understand the types of mutations observed and their phenotypic impact and the likelihood of virologic failure (VF) on a regimen that includes either a ritona...

journal_title：HIV clinical trials

authors： Ross L,Vavro C,Wine B,Liao Q

更新日期：2006-11-01 00:00:00

abstract：PURPOSE:To prospectively determine incidence, prevalence, and extent of lipodystrophy (LD) and associated metabolic changes. METHOD:This was a prospective cohort study. Body habitus changes were determined by anthropometrics, photography, and regional dual-energy X-ray absorptiometry (DXA) scan. Metabolic parameters i...

journal_title：HIV clinical trials

authors： Walmsley S,Cheung AM,Fantus G,Gough K,Smaill F,Azad,Diong C,Raboud J

更新日期：2008-09-01 00:00:00

abstract：PURPOSE:Proven clinical efficacy of protease-sparing regimens (PSR) has been shown. Concerns exist about broad applicability of these regimens in advanced naïve patients. Recent reports have associated a rise in liver enzymes with nevi rapine; however, no data exist with efavirenz. METHOD:17 consecutive antiretroviral...

journal_title：HIV clinical trials

authors： Corales RB,Shrestha NK,Taege AJ,Isada CM,Rehm SJ,Schmitt SK,Gordon SM,Mawhorter SD

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:A safe, effective, easy-to-dose antiretroviral therapy that minimizes hepatic complication risk is essential in optimizing HIV-HCV treatment. Nucleoside-sparing boosted protease inhibitor monotherapy may achieve this goal. METHODS:A prospective, open-label pilot simplification study of once-daily lopinavir/...

journal_title：HIV clinical trials

authors： Cooper C,la Porte C,Tossonian H,Sampalis J,Ackad N,Conway B

更新日期：2012-07-01 00:00:00

abstract：BACKGROUND:Nevirapine, a nonnucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the durable suppression of HIV with nevirapine when used along with other nucleosides in HIV-infected patients who are treated in clinical practice n...

journal_title：HIV clinical trials

authors： Allan PS,Arumainayagam J,Harindra V,Tobin J,Browning M,Yoganathan K,Wade A,Das S

更新日期：2003-07-01 00:00:00

abstract：PURPOSE:To assess the virologic and immunologic response to a boosted double-protease inhibitor (PI) regimen of highly pretreated patients infected with HIV-1 and to examine the role of PI resistance and concentration of serum saquinavir. METHOD:In an open-label prospective study, lopinavir/ritonavir, saquinavir-sgc, ...

journal_title：HIV clinical trials

authors： Smith GH,Boulassel MR,Klien M,Gilmore N,MacLeod J,LeBlanc R,René P,Routy JP,Lalonde RG

更新日期：2005-03-01 00:00:00

abstract：PURPOSE:This retrospective study investigates the effect of prior nucleoside (nucleoside reverse transcriptase inhibitor [NRTI]) experience on 2-year virologic response to an initial protease inhibitor-highly active antiretroviral therapy (PI-HAART) regimen. METHOD:152 patients who started a PI (excluding saquinavir h...

journal_title：HIV clinical trials

authors： Kazanjian P,Tashima K,Hollander T,Kaul D

更新日期：2001-05-01 00:00:00

abstract：:Naturally occurring polymorphisms at positions involved in resistance to antiretroviral agents are frequently seen in HIV-1 non-B subtypes. Although they do not seem to affect significantly the susceptibility to antiretroviral drugs in vitro, they may facilitate the selection of different pathways and/or a more rapid ...

journal_title：HIV clinical trials

authors： Holguín A,Soriano V

更新日期：2002-09-01 00:00:00

abstract：:Tuberculosis and HIV have combined to present a major threat to global public health. Each disease has a negative effect on the other, and mortality in patients with both tuberculosis and HIV is higher than that caused by either condition alone. In regions such as sub-Saharan Africa, as many as a third or more of all ...

journal_title：HIV clinical trials

authors： Schluger NW,Burzynski J

更新日期：2001-07-01 00:00:00

abstract：PURPOSE:Recent trials suggest serious toxicity in HIV-associated non-Hodgkin's lymphoma (NHL) with rituximab (R) and chemotherapy (CT), offsetting the benefit of rituximab. METHOD:We retrospectively reviewed experience with CHOP-R vs. CT in 40 patients with HIV-associated diffuse large B-cell lymphoma (DLBCL) diagnose...

journal_title：HIV clinical trials

authors： Ezzat H,Filipenko D,Vickars L,Galbraith P,Li C,Murphy K,Montaner JS,Harris M,Hogg RS,Vercauteren S,Leger CS,Zypchen L,Leitch HA

更新日期：2007-05-01 00:00:00

abstract：BACKGROUND:Endothelial progenitor cells (EPCs) are bone marrow-derived cells that contribute to vascular repair. EPCs may be reduced in HIV-infected (HIV+) persons, contributing to cardiovascular disease (CVD). Telmisartan is an angiotensin receptor blocker that increases EPCs in HIV-uninfected adults. OBJECTIVE:To as...

journal_title：HIV clinical trials

authors： Lake JE,Seang S,Kelesidis T,Currier JS,Yang OO

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:Raltegravir (RAL) constitutes the first available integrase strand transfer inhibitor (INSTI) available in clinical practice. Three independent pathways have been described to confer resistance to RAL. Secondary mutations with little effect on INSTI susceptibility and additional substitutions with an uncerta...

journal_title：HIV clinical trials

authors： Gutiérrez C,Hernández-Novoa B,Pérez-Elías MJ,Moreno AM,Holguín A,Dronda F,Casado JL,Moreno S

更新日期：2013-01-01 00:00:00

abstract：PURPOSE:The purpose of this study was to evaluate the short-term effects (up to 6 months) of tenofovir disoproxil fumarate (DF) use on renal function in patients being treated for HIV-1 infection. METHOD:The charts of 447 HIV-1-infected patients who received at least three months of tenofovir DF treatment were reviewe...

journal_title：HIV clinical trials

authors： Scott JD,Wolfe PR,Bolan RK,Guyer B

更新日期：2006-03-01 00:00:00

abstract：OBJECTIVES:Statins are lipid-lowering drugs that exhibit anti-Inflammatory and immune-modulatory properties, leading to a reduction of serum levels of C-reactive protein (CRP) in the general population. DESIGN:To assess the anti-inflammatory effects of statins in HIV-infected patients, because very limited data are av...

journal_title：HIV clinical trials

authors： Calza L,Vanino E,Salvadori C,Manfredi R,Colangeli V,Cascavilla A,Di Bari MA,Motta R,Viale P

更新日期：2014-01-01 00:00:00

abstract：PURPOSE:We investigated the evolution of serum lipid levels in HIV-infected pregnant women and the potential effect of antiretroviral treatment during pregnancy using data from a national surveillance study. METHOD:Fasting lipid measurements collected during routine care in pregnancy were used, analyzing longitudinal ...

journal_title：HIV clinical trials

authors： Floridia M,Tamburrini E,Ravizza M,Tibaldi C,Ravagni Probizer MF,Anzidei G,Sansone M,Mori F,Rubino E,Meli M,Dalzero S,Guaraldi G,Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy.

更新日期：2006-07-01 00:00:00

abstract：PURPOSE:Treatment options for HIV-associated lipodystrophy syndrome (HALS) remain limited. The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS. METHOD:Sixty-four subjects received daily ...

journal_title：HIV clinical trials

authors： Macallan DC,Baldwin C,Mandalia S,Pandol-Kaljevic V,Higgins N,Grundy A,Moyle GJ

更新日期：2008-07-01 00:00:00

abstract：OBJECTIVES:Week 96 efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV) was compared to efavirenz (EFV) in subset of 1,096 subjects who received emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in pooled data from 2 phase 3 studies. METHODS:ECHO and THRIVE are double...

journal_title：HIV clinical trials

authors： Nelson MR,Elion RA,Cohen CJ,Mills A,Hodder SL,Segal-Maurer S,Bloch M,Garner W,Guyer B,Williams S,Chuck S,Vanveggel S,Deckx H,Stevens M

更新日期：2013-05-01 00:00:00

abstract：PURPOSE:The objective was to evaluate the impact of an intervention for improving adherence to antiretroviral therapies (HAART) in HIV-infected patients. METHOD:We designed a prospective, controlled, randomized trial to assess the impact of an educational and counseling intervention in addition to standard of care. At...

journal_title：HIV clinical trials

authors： Pradier C,Bentz L,Spire B,Tourette-Turgis C,Morin M,Souville M,Rebillon M,Fuzibet JG,Pesce A,Dellamonica P,Moatti JP

更新日期：2003-03-01 00:00:00

abstract：BACKGROUND:The lack of human resources for health is presently recognized as a major factor limiting scale-up of antiretroviral treatment (ART) programs in resourcelimited settings. The mobilization of public and private partners, the decentralization of care, and the training of non-HIV specialist nurses and general p...

journal_title：HIV clinical trials

authors： Clevenbergh P,Van der Borght SF,van Cranenburgh K,Janssens V,Kitenge Lubangi C,Gahimbaza L,Lange JM,Rinke de Wit TF,Rijckborst H

更新日期：2006-09-01 00:00:00

abstract：:Total eradication of HIV-1 is not yet achievable, in part because reservoirs of latent HIV-1 can develop within lymphoid tissue, the testes, and the central nervous system (CNS). The presence of HIV-1 in the CNS is clinically significant because of its association with the development of HIV dementia, which occurs in ...

journal_title：HIV clinical trials

authors： McGee B,Smith N,Aweeka F

更新日期：2006-05-01 00:00:00